Helsinn Therapeutics (U.S.)

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Helsinn Therapeutics (U.S.) sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).

10 total trials none currently recruiting 10 completed early-phase tilt top decile by trial count

Helsinn Therapeutics (U.S.): 10 sponsored US clinical trials, none currently recruiting.

Helsinn Therapeutics (U.S.) sponsors 10 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 10 completed. 3 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Gastrointestinal Dysmotility, with 1 trials.

Top-decile sponsor footprint

Helsinn Therapeutics (U.S.) ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

A 90/100

10 of 10 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

10 total, page 1 of 1

COMPLETED

Clinical Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma

NCT02296164
COMPLETED Phase 3

Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2)

NCT01387282
COMPLETED Phase 3

Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1)

NCT01387269
COMPLETED Phase 3

Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)

NCT01395914
COMPLETED Phase 2

Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function

NCT01280344
COMPLETED Phase 2

Safety and Efficacy of Ipamorelin for Management of Post-Operative Ileus

NCT00672074
COMPLETED Phase 2

Dose Range Study of Anamorelin in Patients With Non-small Cell Lung Cancer

NCT00622193
COMPLETED Phase 2

Placebo Controlled, Randomized Safety and Efficacy Study of RC-1291 in Cancer Anorexia/Cachexia

NCT00378131
COMPLETED Phase 2

Placebo Controlled, Randomized Safety and Efficacy Study of RC-1291 in Cancer Anorexia/Cachexia.

NCT00267358
COMPLETED Phase 2

Safety and Efficacy of RC-1291 HCl in Patients With Cancer Related Anorexia and Weight Loss

NCT00219817

Phase Distribution

PhaseTrial count
Phase 2 6
Phase 3 3

Therapeutic Areas

Gastrointestinal Dysmotility 1
Cancer Cachexia 1
Cachexia 1
Non-Small Cell Lung Cancer 1

How the Helsinn Therapeutics (U.S.) early-phase archive is shaped

10 indexed studies, none listed as recruiting (0% open); 10 completed (100%).

Phase mix: 3 late (III/IV) vs 6 early (I/II) (early-phase heavy).

Top condition: Gastrointestinal Dysmotility (1 trial), 3 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Helsinn Therapeutics (U.S.): archived-pipeline peers nationwide

Peers matched on 10 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Helsinn Therapeutics (U.S.) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share Helsinn Therapeutics (U.S.)Adamas PharmaceuticalsAdverum BiotechnologiesAevi Genomic Medicine, LLC, a Cerecor companyAgouron Pharmaceuticals10xBio22nd Century Group23andMe3-C Institute for Social Development
Helsinn Therapeutics (U.S.) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Helsinn Therapeutics (U.S.) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 10 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Helsinn Therapeutics (U.S.) page

10 registered trials is a research-attention snapshot, not an endorsement of Helsinn Therapeutics (U.S.) or any single study.

  • None of Helsinn Therapeutics (U.S.)'s trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Gastrointestinal Dysmotility is the condition Helsinn Therapeutics (U.S.) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Gastrointestinal Dysmotility trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Helsinn Therapeutics (U.S.) pipeline card: 10 registered trials from official public datasets.Report a data error.